2018 June, 01 MPI - Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world`s largest cancer congress ASCO 2018 Read more
(WorldNews Denmark)

2018-06-01 Hoersholm, Denmark, June 1, 2018 - Medical Prognosis Institute A/S (`MPI`) hereby announces that clinical data on PARP inhibitor 2X-121 and DRP response prediction validation is to be presented on the world`s largest cancer congress ASCO 2018 on June 1st 2018. Oncology Venture - MPI`s drug development arm - in-licensed the active PARP inhibitor E7449 now called 2X-121 from Eisai in Q2 2017 and present clinical data as well as data demonstrating validation of Oncology Ventures novel DRP®s ability to identify the patients who will benefit from 2X-121 therapy. `We are very proud that we can already now present our clinical data with our PARP inhibitor 2X-121 and our DRP®. 2X-121 is...